8-K: Brainstorm Secures High-Cost Debt Financing

Brainstorm Cell Therapeutics Inc. has entered into a securities purchase agreement for a $182,400 promissory note, receiving $155,000 in net proceeds for working capital.

Summary

• Brainstorm Cell Therapeutics Inc. (BCLI) entered into a Securities Purchase Agreement with Vanquish Funding Group Inc. on October 31, 2025.
• The agreement involves a promissory note with a principal amount of $182,400, which includes a $22,400 Original Issue Discount (OID).
• The Company received $155,000 in funds after accounting for $5,000 in combined legal and due diligence fees.
• The Note bears interest at 12% per annum, which increases to 22% if payments are not made timely.
• The Note matures on August 30, 2026, with scheduled payments of $102,144 on April 30, 2026, and $25,536 on May 30, June 30, July 30, and August 30, 2026, totaling $204,288.
• Upon an event of default, the Note is convertible into common stock at a 35% discount to the lowest trading price over the 10 trading days prior to conversion, subject to a 4.99% beneficial ownership limitation.
• Vanquish Funding Group Inc. may provide additional financing tranches of up to $2 million in aggregate over the next twelve months, subject to further agreement.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the high cost of capital (12% interest, 22% on default), significant original issue discount, and highly dilutive conversion terms upon default. While the funding provides immediate liquidity, the unfavorable terms suggest financial strain and potential future shareholder value erosion.

Positives

• Secured immediate funding of $155,000 for general working capital purposes.
• The agreement provides for potential additional financing of up to $2 million over the next 12 months, subject to further agreement, offering a potential future capital source.
• The Company has the right to prepay the outstanding Note in full at any time without penalty, with prepayment discounts ranging from 95% to 98% of the outstanding amount depending on the prepayment period.

Negatives

• The promissory note carries a high interest rate of 12%, escalating to 22% upon timely payment failure, indicating a high cost of capital.
• A significant Original Issue Discount (OID) of $22,400 means the Company received less cash ($160,000) than the principal amount of the note ($182,400).
• The net proceeds to the Company were further reduced by $5,000 for legal and due diligence fees, resulting in only $155,000 in actual cash received.
• Conversion into common stock upon an event of default at a 35% discount to the market price could lead to substantial dilution for existing shareholders.
• Various events of default trigger severe penalties, including immediate payment of 150% (or 175% for certain defaults) of the outstanding principal and interest, or conversion at the deeply discounted rate.

Risks

• Potential for significant shareholder dilution if the Note converts into common stock due to an event of default, given the 35% discount to market price.
• The high interest rate and potential for default interest (22%) increase the Company's debt servicing burden.
• Failure to meet scheduled payments or other covenants could trigger an event of default, leading to accelerated repayment obligations or forced conversion.
• The Company must maintain its listing on at least one of the OTC, Nasdaq, or NYSE exchanges; delisting constitutes an event of default.
• The Company must reserve three times the number of shares actually issuable upon full conversion of the Note; failure to do so is an event of default.

Future Outlook

Vanquish Funding Group Inc. may provide additional tranches of financing up to $2 million in aggregate over the next twelve months, subject to further agreement between the parties. The Company intends to use the proceeds for general working capital purposes.

Management Comments

• Chaim Lebovits, President and Chief Executive Officer, signed the report on behalf of Brainstorm Cell Therapeutics Inc.

Industry Context

This type of high-cost, dilutive debt financing is often utilized by smaller biotechnology or pharmaceutical companies, particularly those in pre-commercial stages or facing significant R&D expenses without substantial revenue streams. It suggests that the company may have limited access to traditional, less dilutive equity or debt markets, potentially due to its risk profile, stage of development, or current financial health. Such financing can provide crucial short-term liquidity but often comes with terms that are unfavorable to existing shareholders.

Comparison to Industry Standards

• The 12% interest rate, escalating to 22% upon default, is significantly higher than typical corporate debt for established companies, which often secure financing at prime rates plus a spread (e.g., 4-8%). This indicates a higher perceived risk by the lender.
• The 35% discount on conversion into common stock upon default is a substantial dilutive measure, far exceeding standard anti-dilution provisions in more favorable financing agreements.
• The Original Issue Discount (OID) of $22,400 on a $182,400 note (approximately 12.3% of principal) is a notable cost, effectively reducing the immediate capital received and increasing the true cost of borrowing compared to debt issued at par.
• Compared to larger, revenue-generating biotech firms that can access syndicated loans or investment-grade bonds, Brainstorm's terms reflect a more distressed or high-risk financing environment, similar to bridge loans or venture debt often seen in early-stage or financially constrained companies.

Stakeholder Impact

• Shareholders face potential significant dilution if the promissory note converts into common stock due to an event of default, given the 35% discount to market price.
• Creditors (Vanquish Funding Group Inc.) benefit from high interest rates, strong default protections, and favorable conversion terms, indicating a strong position in this financing arrangement.
• The Company's ability to continue operations is supported by the immediate capital infusion, which is positive for employees and ongoing business activities, but the high cost of capital could strain future financial performance.

Next Steps

• Make scheduled principal and interest payments on the promissory note, starting April 30, 2026, through August 30, 2026.
• Potentially pursue additional financing tranches of up to $2 million from Vanquish Funding Group Inc. within the next twelve months, subject to further agreement.
• Maintain compliance with all covenants of the Note and Securities Purchase Agreement, including 1934 Act reporting requirements and stock exchange listing.

Key Dates

Recommendation

The company secured immediate working capital, which is positive for short-term operations and addresses an apparent need for liquidity. However, the terms of the promissory note are highly unfavorable, including a high interest rate (12% increasing to 22% on default), a significant original issue discount, and highly dilutive conversion features (35% discount to market price upon default). While the funding provides a lifeline, these terms suggest underlying financial challenges or limited access to more attractive financing options. Investors should monitor the company's ability to meet repayment obligations and avoid default, as conversion would significantly impact existing shareholder value. Given the immediate capital infusion but the high cost and dilutive potential, a 'hold' recommendation is appropriate for existing investors to assess future developments, while new investors might find the risk-reward profile less appealing.

Keywords

Brainstorm Cell Therapeutics, BCLI, Promissory Note, Debt Financing, Capital Raise, Dilution, SEC Filing, 8-K, Vanquish Funding Group, Working Capital